Cargando…

Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)

BACKGROUND: Recurrent bronchiectasis exacerbations are related to deterioration of lung function, progression of the disease, impairment of quality of life, and to an increased mortality. Improved detection of exacerbations has been accomplished in chronic obstructive pulmonary disease through the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Artaraz, Amaia, Crichton, Megan L., Finch, Simon, Abo-Leyah, Hani, Goeminne, Pieter, Aliberti, Stefano, Fardon, Thomas, Chalmers, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958700/
https://www.ncbi.nlm.nih.gov/pubmed/31931782
http://dx.doi.org/10.1186/s12931-019-1272-y
_version_ 1783487470408564736
author Artaraz, Amaia
Crichton, Megan L.
Finch, Simon
Abo-Leyah, Hani
Goeminne, Pieter
Aliberti, Stefano
Fardon, Thomas
Chalmers, James D.
author_facet Artaraz, Amaia
Crichton, Megan L.
Finch, Simon
Abo-Leyah, Hani
Goeminne, Pieter
Aliberti, Stefano
Fardon, Thomas
Chalmers, James D.
author_sort Artaraz, Amaia
collection PubMed
description BACKGROUND: Recurrent bronchiectasis exacerbations are related to deterioration of lung function, progression of the disease, impairment of quality of life, and to an increased mortality. Improved detection of exacerbations has been accomplished in chronic obstructive pulmonary disease through the use of patient completed diaries. These tools may enhance exacerbation reporting and identification. The aim of this study was to develop a novel symptom diary for bronchiectasis symptom burden and detection of exacerbations, named the BEST diary. METHODS: Prospective observational study of patients with bronchiectasis conducted at Ninewells Hospital, Dundee. We included patients with confirmed bronchiectasis by computed tomography, who were symptomatic and had at least 1 documented exacerbation of bronchiectasis in the previous 12 months to participate. Symptoms were recorded daily in a diary incorporating cough, sputum volume, sputum colour, dyspnoea, fatigue and systemic disturbance scored from 0 to 26. RESULTS: Twenty-one patients were included in the study. We identified 29 reported (treated exacerbations) and 23 unreported (untreated) exacerbations over 6-month follow-up. The BEST diary score showed a good correlation with the established and validated questionnaires and measures of health status (COPD Assessment Test, r = 0.61, p = 0.0037, Leicester Cough Questionnaire, r = − 0.52,p = 0.0015, St Georges Respiratory Questionnaire, r = 0.61,p < 0.0001 and 6 min walk test, r = − 0.46,p = 0.037). The mean BEST score at baseline was 7.1 points (SD 2.2). The peak symptom score during exacerbation was a mean of 16.4 (3.1), and the change from baseline to exacerbation was a mean of 9.1 points (SD 2.5). Mean duration of exacerbations based on time for a return to baseline symptoms was 15.3 days (SD 5.7). A minimum clinically important difference of 4 points is proposed. CONCLUSIONS: The BEST symptom diary has shown concurrent validity with current health questionnaires and is responsive at onset and recovery from exacerbation. The BEST diary may be useful to detect and characterise exacerbations in bronchiectasis clinical trials.
format Online
Article
Text
id pubmed-6958700
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69587002020-01-17 Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST) Artaraz, Amaia Crichton, Megan L. Finch, Simon Abo-Leyah, Hani Goeminne, Pieter Aliberti, Stefano Fardon, Thomas Chalmers, James D. Respir Res Research BACKGROUND: Recurrent bronchiectasis exacerbations are related to deterioration of lung function, progression of the disease, impairment of quality of life, and to an increased mortality. Improved detection of exacerbations has been accomplished in chronic obstructive pulmonary disease through the use of patient completed diaries. These tools may enhance exacerbation reporting and identification. The aim of this study was to develop a novel symptom diary for bronchiectasis symptom burden and detection of exacerbations, named the BEST diary. METHODS: Prospective observational study of patients with bronchiectasis conducted at Ninewells Hospital, Dundee. We included patients with confirmed bronchiectasis by computed tomography, who were symptomatic and had at least 1 documented exacerbation of bronchiectasis in the previous 12 months to participate. Symptoms were recorded daily in a diary incorporating cough, sputum volume, sputum colour, dyspnoea, fatigue and systemic disturbance scored from 0 to 26. RESULTS: Twenty-one patients were included in the study. We identified 29 reported (treated exacerbations) and 23 unreported (untreated) exacerbations over 6-month follow-up. The BEST diary score showed a good correlation with the established and validated questionnaires and measures of health status (COPD Assessment Test, r = 0.61, p = 0.0037, Leicester Cough Questionnaire, r = − 0.52,p = 0.0015, St Georges Respiratory Questionnaire, r = 0.61,p < 0.0001 and 6 min walk test, r = − 0.46,p = 0.037). The mean BEST score at baseline was 7.1 points (SD 2.2). The peak symptom score during exacerbation was a mean of 16.4 (3.1), and the change from baseline to exacerbation was a mean of 9.1 points (SD 2.5). Mean duration of exacerbations based on time for a return to baseline symptoms was 15.3 days (SD 5.7). A minimum clinically important difference of 4 points is proposed. CONCLUSIONS: The BEST symptom diary has shown concurrent validity with current health questionnaires and is responsive at onset and recovery from exacerbation. The BEST diary may be useful to detect and characterise exacerbations in bronchiectasis clinical trials. BioMed Central 2020-01-13 2020 /pmc/articles/PMC6958700/ /pubmed/31931782 http://dx.doi.org/10.1186/s12931-019-1272-y Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Artaraz, Amaia
Crichton, Megan L.
Finch, Simon
Abo-Leyah, Hani
Goeminne, Pieter
Aliberti, Stefano
Fardon, Thomas
Chalmers, James D.
Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)
title Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)
title_full Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)
title_fullStr Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)
title_full_unstemmed Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)
title_short Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)
title_sort development and initial validation of the bronchiectasis exacerbation and symptom tool (best)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958700/
https://www.ncbi.nlm.nih.gov/pubmed/31931782
http://dx.doi.org/10.1186/s12931-019-1272-y
work_keys_str_mv AT artarazamaia developmentandinitialvalidationofthebronchiectasisexacerbationandsymptomtoolbest
AT crichtonmeganl developmentandinitialvalidationofthebronchiectasisexacerbationandsymptomtoolbest
AT finchsimon developmentandinitialvalidationofthebronchiectasisexacerbationandsymptomtoolbest
AT aboleyahhani developmentandinitialvalidationofthebronchiectasisexacerbationandsymptomtoolbest
AT goeminnepieter developmentandinitialvalidationofthebronchiectasisexacerbationandsymptomtoolbest
AT alibertistefano developmentandinitialvalidationofthebronchiectasisexacerbationandsymptomtoolbest
AT fardonthomas developmentandinitialvalidationofthebronchiectasisexacerbationandsymptomtoolbest
AT chalmersjamesd developmentandinitialvalidationofthebronchiectasisexacerbationandsymptomtoolbest